BEARINGPOINT//BEYOND
12.2.2020 09:02:05 CET | Business Wire | Press release
BearingPoint//Beyond today launched new research that suggests communications service providers (CSPs) are failing to develop the business-to-business (B2B) solutions that are critical to the commercial success of 5G. The study also finds that businesses around the world are more ambitious about the role CSPs will play in 5G than CSPs are themselves.
5G is the first generation of mobile technology that will have a bigger impact on businesses than on consumers1 . On average across Europe, Asia and North America, CSPs anticipate a 15% increase in current revenues from B2B 5G services (significant in an industry struggling with sub-2%2 compound annual revenue growth). 75% of enterprises and small to medium businesses (SMBs) believe 5G will be important to their business citing speed, reliability and more advanced solutions as key reasons.
Growing disconnect
“Businesses want to buy 5G, CSPs want to sell 5G. The problem is that CSPs want to just sell connectivity and standardized ‘connectivity plus infrastructure’ products, while businesses want to buy more sophisticated, complete solutions that better fit their needs and require the integration of multiple technologies from multiple players,” says Angus Ward, CEO, BearingPoint//Beyond.
CSPs must look to broaden their role from communications to providing the broader technologies that support business customers. They need to collaborate with customers to co-innovate and co-create more compelling and sophisticated solutions with a wide range of ecosystem partners, including OTTs, web-scale companies, vertical specialists, even competitors, to meet the demands of business customers.
“CSPs must learn the art of ecosystem orchestration if they want to monetize 5G at scale,” cautions Ward. “Businesses don’t want to build these solutions themselves. And while the vast majority would happily work with CSPs, they’re not waiting around - businesses are already partnering with other companies to solve their business problems. They must move quickly.”
Regional insights & actions
Europe:
- CSPs are pinning their 5G hopes on 4G business models - consumer services and enterprise connectivity. Just a third of CSPs believe their role will extend beyond simple connectivity plus infrastructure offerings. Only 10% of European CSPs believe they will become ecosystem orchestrators.
- 92% of European businesses believe CSPs have a bigger role to play than just providing communications and connectivity. Almost seven in 10 want CSPs to offer 5G solutions that combine their assets with those of partners.
- Enterprises want to work with CSPs to develop 5G solutions because they can orchestrate ecosystems, manage complex programs and understand 5G technology.
“European CSPs must re-engineer their mindsets, and businesses, to capitalize on this opportunity,” says Ward.
North America:
- Confidence and ambition are highest amongst North American CSPs.
- More than three quarters of CSPs agree that creating vertical specific solutions using ecosystems of partners represents a big 5G opportunity. 40% expect to become ecosystem orchestrators.
- North American businesses agree: 96% believe CSPs have a bigger role to play – citing ecosystem orchestration, complex program management and flexibility as reasons they want to work with CSPs to develop 5G use cases.
“North American CSPs now need to act fast, building the right partnerships and the right IT platform to enable them to operate an ecosystem required to meet the expectations of their business customers,” recommends Ward.
Asia:
- More attention is being paid to 5G connectivity-driven models than higher value solutions by Asian CSPs. Just 17% see themselves as ecosystem orchestrators.
- Yet 94% of Asian businesses believe that CSPs can do more than provide communications and connectivity – nearly seven in 10 think CSPs should offer sophisticated services using an ecosystem of partners.
- Again, ecosystem orchestration, complex program management and their knowledge of 5G make CSPs attractive partners for Asian businesses.
“Enterprises and SMBs alike are practically crying out to work with CSPs on 5G solutions - Asian CSPs must heed this call, shake off their doubts and act quickly,” advises Ward.
The time is NOW
“In 5G B2B terms, CSPs are pushing at an open door. 98% of European businesses, 92% of Asian businesses and 87% of North American businesses are willing to buy advanced solutions from their CSP. But these must be solutions that address their specific business needs. The only way CSPs can achieve this is orchestrate ecosystems of partners to co-create compelling new solutions that embed 5G,” continues Ward.
“If CSPs continue to define their role too narrowly, they will miss out entirely on the high margin opportunities in B2B 5G. Connectivity represents a tiny portion - as low as 5% - of the revenue for each use case. By not taking a lead now, CSPs are gifting the majority of 5G revenues to a new generation of OTTs. The much higher cost of 5G networks means they are seriously jeopardising the ability to monetize their 5G investments. CSPs must quickly master the art of ecosystem orchestration if they want to monetize 5G at scale. If they don’t, technology providers and vertical solution providers will. In Asia, CSPs are already seen as ‘second choice’ partners for businesses building 5G use cases, in North America CSPs rank third, in Europe, fourth. CSPs have to demonstrate ambition and make up ground quickly. Inaction will cost CSPs billions of dollars,” concludes Ward.
To download a free copy of ‘If B2B is the ‘North Star’ for 5G revenues: how do CSPs get there?’, please visit https://www.bearingpointbeyond.com/en/industries/5g/5g-b2b/ .
- ENDS -
Methodology
BearingPoint//Beyond commissioned a large-scale primary research study to examine the real attitudes of both CSPs and business customers towards 5G, and the potential role of CSPs in the 5G era. Conducted and analyzed in late-2019, research firm Coleman Parkes interviewed 250 technology decision makers from 100 enterprises and 150 SMBs - in verticals such as manufacturing, financial services, retail, health, education, transportation and media - across Europe, Asia and North America. 90 senior executives within CSPs were also surveyed from these three regions.
At Mobile World Congress 2020
Angus Ward will be speaking on: “A Next-Gen Network demands a Next-Gen Organization”, Tuesday, 25th February: 3:15pm – Hall 4, Auditorium 5. BearingPoint//Beyond’s Head of Marketing, Michal Harris, will be speaking on “Unlocking the Value of Partner Ecosystems”, Monday, 24th February: 3:45pm – Hall 4, Auditorium 4.
About BearingPoint//Beyond
BearingPoint//Beyond is a rapidly growing SaaS-based BSS and digital platform solution provider helping organizations to reinvent their business model and grow revenue by utilizing digital platforms and partner ecosystems.
Our digital platform solutions are designed to help businesses experiment, launch and monetize new offerings at speed, with minimum risk and cost; building connections between technologies and partners, enabling them to collaborate, co-innovate and expand reach with an ecosystem of partners while taking advantage of new technologies such as cloud, IoT AI, 5G and more. This brings organizations closer to their customers, helping drive higher efficiency and automation, to become more agile in the face of competition. BearingPoint//Beyond is owned by BearingPoint.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success. The third unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 75 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
BearingPoint//Beyond home page: https://www.bearingpointbeyond.com
Homepage: www.bearingpoint.com
Annual Report: www.bearingpoint.com/en/about-us/annual-report/
LinkedIn: http://www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
1
GSMA Intelligence, “The 5G era report”, 2017
2
Ovum, “Mobile Subscription and Revenue Forecast Report: 2019-24”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
